ImmuPharma plc
IMM.L · LSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | £0 | £0 | £0 | £0 |
| - Cash | £0 | £0 | £0 | £0 |
| + Debt | £0 | £0 | £0 | £0 |
| Enterprise Value | £0 | £0 | £0 | £0 |
| Revenue | £0 | £0 | £0 | £0 |
| % Growth | – | – | -100% | – |
| Gross Profit | -£0 | -£0 | -£0 | £0 |
| % Margin | – | – | – | 100% |
| EBITDA | -£0 | -£0 | -£0 | -£0 |
| % Margin | – | – | – | -7,353.6% |
| Net Income | -£0 | -£0 | -£0 | -£0 |
| % Margin | – | – | – | -6,906.6% |
| EPS Diluted | -0.006 | -0.008 | -0.013 | -0.033 |
| % Growth | 25.9% | 35.7% | 61.2% | – |
| Operating Cash Flow | -£0 | -£0 | -£0 | -£0 |
| Capital Expenditures | -£0 | £0 | -£0 | -£0 |
| Free Cash Flow | -£0 | -£0 | -£0 | -£0 |